ICE Pharma launches the project Check-up your bias to promote gender equality in workplace
Bias, especially in the workplace, affects all of us. Even if we are willing to give the best of ourselves, sometimes we unknowingly engage in different behaviors according to...
ICE Pharma will attend the DCAT Week in New York City
We are heading to DCAT Week, one of the leading pharmaceutical event in US, held every year in New York City. We look forward to welcoming you in our...
Fourth research publication in collaboration with ICE Pharma and Ferrier Research Institute
We are proud to announce the publication of another scientific paper coming from the collaboration of ICE Pharma with the Ferrier Research Institute. This paper relates to Parkinson’s Disease...
ICE Pharma obtained the certifications ISO 45001 and ISO 50001 in its sites in Italy and New Zealand.
From planning, construction and operation of production facilities, we continue to implement global process safety standards and improve measures for incident prevention in all our plants across the world....
A recent study suggest that UDCA may help prevent Covid infection
ICE Pharma has been featured in an article in the Italian press, Il corriere della sera, concerning the huge increase in requirement for the drug Ursodeoxycholic acid in China. ...
New Zealand Pharmaceuticals achieved the FernMark license
It’s with great pleasure that we announce the achievement by our subsidiary, NZP, of the renowned FernMark license. The FernMark is a mark of trust that communicates a product’s...
ICE Pharma published the Sustainability Report 2021/2022
During 2022, ICE Pharma developed a long-term sustainability strategy and a short-term roadmap that will guide our actions for the next three years. We describe the strategic choices that...
ICE Pharma attended CPHI Frankfurt 2022
ICE Pharma attended the main pharma industry exhibition of 2022, CPHI, which was held in Frankfurt from 1 to 3 of November. During the three days event, we had...
ICE Pharma acquires Iwaki manufacturing site from Mitbubishi API corporation
We are pleased to announce that on May 2nd ICE Pharma completed the purchase of the Iwaki Ursodeoxycholic Acid (“UDCA”) manufacturing site from Mitsubishi API Corporation. This transaction represents...
Third research publication in collaboration with ICE Pharma and Ferrier Research Institute
Synthesis of Novel C/D Ring Modified Bile Acids Bile acid receptors have been identified as important targets for the development of new therapeutics to treat various metabolic and inflammatory...
Bile acids in medicine. Review article by ICE Pharma
Bile acids: From acient Chinese medicines to modern treatments In 1999 the landscape evolved further when, bile acids and bile salts were shown to have hormonal activity as bile...
Second research publication in collaboration with ICE Pharma and Ferrier Research Institute
Synthesis of 12β-methyl-18-nor-avicholic acid analogues as potential TGR5 agonists In the quest for new modulators of the Farnesoid-X (FXR) and Takeda G-protein-coupled (TGR5) receptors, bile acids are a popular...